{"ticker": {"uuid": "ae9f4316-61ea-466d-9bd1-f33dd100d7c3", "symbol": "SGP", "name": "SpyGlass Pharma, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Top Spyglass Pharma (SGP) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE44LThrdVVQVlpTN0Y4SEtoZEc2WDF2QS16Um5hUDRFSHVXVGg2THJsTUtyQVh5QVdWR084WE9iNm0zTHJIS3BXOVVfRi0yeENkaC0wNUFDUVlwNHltQXMtZExHcWNmMmppZDVFb09STmRvTjRvSFdsS0hDOVNKS00?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T01:19:40+00:00", "published_display": "14 Jul 2026 01:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index", "summary": "SpyGlass Pharma, Inc. (NasdaqGS:SGP) has been added to the Russell Microcap Growth Benchmark Index. This inclusion follows several other additions for the company to various Russell indices, including the Russell 2000, Russell Microcap Value, and Russell 3000E. SpyGlass Pharma is", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08cf327", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:39:59", "published_display": "29 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index", "summary": "SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been added to the Russell 2000 Index. This inclusion follows several other recent index additions, including the S&P Global BMI Index and the S&P TMI Index, highlighting the company's growing recognition in the financial markets. The opht", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-2000-index-ce7f5fdfdc8ef426", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:57:00", "published_display": "29 Jun 2026 17:57", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark", "summary": "SpyGlass Pharma, Inc. (NasdaqGS:SGP) has been added to the Russell 2000 Value Benchmark, according to an announcement published on MarketScreener. The company specializes in ophthalmic drug delivery, with its flagship product being the SpyGlass Drug Delivery Platform designed to ", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-2000-value-benchmark-ce7f5fdfdb89f020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:12:03", "published_display": "29 Jun 2026 16:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark", "summary": "SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been included in the Russell 2000 Growth Benchmark. This news follows several other recent updates for the company, including presentations at major healthcare conferences and its addition to the S&P Global BMI Index and S&P TMI Index, hi", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-2000-growth-benchmark-ce7f5fded18cf225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:03", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article provides limited financial information for SpyGlass Pharma, Inc. (NASDAQ: SGP), specifically mentioning its \"Price to earnings forward.\" The full data for this metric is not displayed in the provided text. The page appears to be a financial data portal from TradingVi", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T07:41:32", "published_display": "29 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP)", "summary": "This article provides key financial data and analyst estimates for SpyGlass Pharma, Inc. (NASDAQ: SGP). It covers the company's current stock price, historical performance, future price forecasts from analysts, and recent financial results including earnings and revenue. The info", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:56", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article focuses on the \"Price to sales forward\" financial metric for SpyGlass Pharma, Inc. (NASDAQ: SGP). It appears to be a stub or a section of a larger financial data page, indicating that this specific data point is provided by TradingView, with underlying data from ICE ", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:40:56", "published_display": "26 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article provides financial data for SpyGlass Pharma, Inc. (NASDAQ: SGP), specifically focusing on its enterprise value to revenue forward. The content is presented within the context of a financial platform, indicating a focus on market analytics and company performance metr", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:39:59", "published_display": "26 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article provides the \"Price to book forward\" for SpyGlass Pharma, Inc. (NASDAQ: SGP). It appears to be a financial data snippet from TradingView, indicating no trades and a market closed status, presenting the fundamental value for the specified period.", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:26", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP", "summary": "As of June 15, 2026, Spyglass Pharma (SGP) had a short interest of 1.01 million shares, representing 3.03% of its public float, an 11.57% decrease from the previous report. The short interest ratio is 14.3 days to cover. This indicates that while still considered high, investor s", "url": "https://www.marketbeat.com/stocks/NASDAQ/SGP/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T03:40:22", "published_display": "26 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index", "summary": "SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been included in the S&P Global BMI Index. The company, which specializes in ophthalmic drug delivery solutions, was added to the index as announced on June 21, 2026, at 10:30 PM EDT. This inclusion highlights SpyGlass Pharma's growing pr", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-s-p-global-bmi-index-ce7f5cd3d881f626", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T02:41:28", "published_display": "22 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Shannon Trevi\u00f1o as general counsel to support Phase 3 trials and commercialization plans.", "summary": "SpyGlass Pharma has appointed Shannon Trevi\u00f1o as its new general counsel, leveraging her extensive legal and leadership experience, including guiding Inari Medical through a $4.9 billion acquisition. Her appointment is strategic as SpyGlass advances its BIM-IOL System through Pha", "url": "https://pluang.com/en/news-feed/spyglass-pharma-tunjuk-shannon-trevino-sebagai-general-counsel", "source_name": "Pluang", "published_at": "2026-06-16T11:40:48", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GC who helped guide Inari through $4.9B Stryker acquisition joins SpyGlass", "summary": "SpyGlass Pharma (Nasdaq: SGP) has appointed Shannon Trevi\u00f1o as its new General Counsel. Trevi\u00f1o previously served as General Counsel at Inari Medical, where she played a key role in its $4.9 billion acquisition by Stryker, and brings extensive experience in corporate, M&A, and se", "url": "https://www.stocktitan.net/news/SGP/spy-glass-pharma-appoints-shannon-trevino-as-general-m51ywidinhkb.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:09:11", "published_display": "16 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Taps Shannon Trevi\u00f1o as General Counsel", "summary": "SpyGlass Pharma Inc., an Aliso Viejo-based biopharmaceutical company, has appointed Shannon Trevi\u00f1o as its new General Counsel. Trevi\u00f1o previously served as general counsel and corporate secretary at Inari Medical, which was acquired by Stryker Corp. for $4.9 billion. This appoin", "url": "https://www.ocbj.com/healthcare/spyglass-taps-shannon-trevino-as-general-counsel/", "source_name": "Orange County Business Journal", "published_at": "2026-06-15T17:09:45", "published_display": "15 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Shannon Trevi\u00f1o as general counsel", "summary": "SpyGlass Pharma has appointed Shannon Trevi\u00f1o as its new general counsel. Trevi\u00f1o brings extensive experience from Inari Medical, where she oversaw legal and compliance, including a $4.9 billion acquisition by Stryker, and her prior work advising early and growth-stage companies.", "url": "https://www.investing.com/news/company-news/spyglass-pharma-appoints-shannon-trevino-as-general-counsel-93CH-4742019", "source_name": "Investing.com", "published_at": "2026-06-15T13:10:30", "published_display": "15 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc. Announces Appointment of Shannon Trevi\u00f1o to General Counsel", "summary": "SpyGlass Pharma, Inc. has announced the appointment of Shannon Trevi\u00f1o as its new General Counsel. Ms. Trevi\u00f1o brings extensive experience in corporate, M&A, and securities law within the healthcare sector, having previously served as General Counsel and Corporate Secretary at In", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-announces-appointment-of-shannon-trevi-o-to-general-counsel-ce7f5cdedd8ff72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-15T13:09:45", "published_display": "15 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Shannon Trevi\u00f1o as general counsel By Investing.com", "summary": "SpyGlass Pharma has appointed Shannon Trevi\u00f1o as its new general counsel. Trevi\u00f1o brings extensive experience, having previously served as General Counsel and Corporate Secretary at Inari Medical, where she managed legal and compliance during a major acquisition. SpyGlass Pharma,", "url": "https://ca.investing.com/news/stock-market-news/spyglass-pharma-appoints-shannon-trevino-as-general-counsel-93CH-4690697", "source_name": "Investing.com Canada", "published_at": "2026-06-15T12:09:45", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing", "summary": "SpyGlass Pharma has appointed Mike Pinder as Vice President, Marketing, effective May 18, 2026. Pinder brings over 20 years of ophthalmology commercial launch experience and will be responsible for building and leading the company's marketing function as it advances its Bimatopro", "url": "https://www.visionmonday.com/eyecare/article/spyglass-pharma-appoints-mike-pinder-as-vice-president-marketing/", "source_name": "VisionMonday.com", "published_at": "2026-06-03T04:09:39", "published_display": "03 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com", "summary": "SpyGlass Pharma announced the appointment of Mike Pinder as VP of marketing. Pinder brings significant ophthalmology commercial launch experience and will lead the marketing function as the company advances its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials. This", "url": "https://za.investing.com/news/stock-market-news/spyglass-pharma-appoints-mike-pinder-as-vp-of-marketing-93CH-4310174", "source_name": "Investing.com South Africa", "published_at": "2026-06-02T18:39:16", "published_display": "02 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Mike Pinder as VP of marketing", "summary": "SpyGlass Pharma has appointed Mike Pinder as Vice President of Marketing. Pinder brings over 20 years of ophthalmology commercial launch experience and will lead the marketing function as the company advances its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials. Th", "url": "https://www.investing.com/news/company-news/spyglass-pharma-appoints-mike-pinder-as-vp-of-marketing-93CH-4721851", "source_name": "Investing.com", "published_at": "2026-06-02T12:39:20", "published_display": "02 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drop-free glaucoma BIM-IOL system taps veteran marketer", "summary": "SpyGlass Pharma (Nasdaq: SGP) has appointed Mike Pinder as Vice President, Marketing, to lead commercialization efforts for its Bimatoprost Drug Pad-IOL System (BIM-IOL System). Pinder brings over 20 years of ophthalmology marketing experience from companies like Astellas, Novart", "url": "https://www.stocktitan.net/news/SGP/spy-glass-pharma-appoints-mike-pinder-as-vice-president-vnpc0wi41cbx.html", "source_name": "Stock Titan", "published_at": "2026-06-02T11:39:20", "published_display": "02 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma (SGP) Slides 2.29% as Stock Approaches Critical Support at $17.0 - Liquidity Sweep", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPQnNLTjZiREJ5LXVYc2tMYzVvR0I3QVhZQlNsVTc5TkNFdE45SnZTdWEyNkllRmkteG5OTjFvMlVzN0hNRlg5V1FlTWdlbU4ycVRxT3dLQW52cTF0eDUxVlpoRngwX0NZXzY0WWhZVHl5ZTZIc0taOU8wVnA4UHRfYjZ5dkRDcnFJWElqM1kxWm5DWGI0d1RSUHV6ZUp0Z0RBeVJteXVUSTY0dlFLcG5oYldR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma to Participate in Upcoming Investor Conferences", "summary": "SpyGlass Pharma, Inc. (Nasdaq: SGP) announced its participation in three upcoming investor conferences in May and June 2026: the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Ex", "url": "https://www.sahmcapital.com/news/content/spyglass-pharma-to-participate-in-upcoming-investor-conferences-2026-05-21", "source_name": "Sahm", "published_at": "2026-05-26T17:39:20", "published_display": "26 May 2026 17:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma execs set for three June healthcare investor events", "summary": "SpyGlass Pharma (Nasdaq: SGP) announced its executive management will participate in three upcoming investor conferences focused on healthcare and ophthalmology in May and June 2026. These events include the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare", "url": "https://www.stocktitan.net/news/SGP/spy-glass-pharma-to-participate-in-upcoming-investor-v6a13ma3qq99.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:59:58", "published_display": "21 May 2026 11:59", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Secures Billing Code for IOL Platform", "summary": "SpyGlass Pharma Inc. has secured a new add-on Category III CPT Code for its intraocular lens (IOL) platform, which delivers glaucoma medication for up to three years. The Aliso Viejo-based company is currently in Phase 3 trials and aims for FDA submission by 2028 and commercial l", "url": "https://www.ocbj.com/healthcare/spyglass-secures-billing-code-for-iol-platform/", "source_name": "Orange County Business Journal", "published_at": "2026-05-19T23:38:56", "published_display": "19 May 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma: New add-on CPT code supports BIM-IOL System", "summary": "The American Medical Association has approved a new add-on Category III CPT code for intraocular lens prosthesis-mounted drug-eluting implants, supporting SpyGlass Pharma's investigational Bimatoprost Drug Pad-IOL (BIM-IOL) System. This system aims to deliver bimatoprost for thre", "url": "https://glance.eyesoneyecare.com/stories/2026-05-19/spyglass-pharma-new-add-on-cpt-code-supports-bim-iol-system/", "source_name": "Eyes On Eyecare", "published_at": "2026-05-19T18:38:56", "published_display": "19 May 2026 18:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System", "summary": "SpyGlass Pharma announced that the AMA's CPT Editorial Panel approved a new add-on Category III CPT code for its Bimatoprost Drug Pad-IOL System (BIM-IOL System). This code will support reimbursement for surgeons using the device in conjunction with cataract surgery, aiming to im", "url": "https://finance.yahoo.com/sectors/healthcare/articles/spyglass-pharma-announces-add-category-120000782.html", "source_name": "Market source", "published_at": "2026-05-18T20:10:26", "published_display": "18 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/spyglass-pharma-reports-first-quarter-200500962.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE85QlJzV0Iwb1pibVMzWGNtQnFkczFCZXd3aC15dTRaOHBxUHFKSS1vSUpaNUZieUVsLVJvTmpnMWdobFg4cVJtVWMzRi1CMFc2YlRWcFdDbVNnWDR6VEZRZFZQODE?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-18T04:54:39+00:00", "published_display": "18 Feb 2026 04:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE5QMDVYbjlnZUxpc1BHMzlQampPbU13dFRqcUg2Vi11S1dXbHV0ODVUeGdvbjFLVDhxWHBRLWVVV0lpVDJPYlJvbldlQlhOYXc4UjhUY19lYlU?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-17T17:53:41+00:00", "published_display": "17 Feb 2026 17:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Stock Forecast and Price Target 2026 $SGP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFA3M3RUa1Y5NUtfNWI5czZRcDdSMFc4bGRDcGJnZVdhQTR2eU43Slo3VTRNM3BUaHBZUGtlOTFsS0ZyWU5HejFiUjJCNHVJR1VxT0VINnJ6QkhiZXR3dFNOZUJhN3o?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-17T17:48:38+00:00", "published_display": "17 Feb 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Announces Closing of Initial Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxOTU1pV0YwTzBOM0FSQUFvMUlqS25TMDBRMksyRGVYS00wYzJaTkdMdlY0WXE2QXhVU2I1czJIWEIwOHhmNTAzdWRnSktha3IxNTJWV19nVEpJdm1zZHdPTmxkNFpoYWl5cG1MUXlEeUMyVkNfeUw2V2h2UnRfSERhMXc3LXQwb0EzZzJLQldJVXZKenhzYnhMaU1BaDZpVFA3c2d0bWk3MUpVRUM4S1lZbk1XOGRJYXdpa210LTBVMTFodHdRVC11T2xqbWVpYTVMdWZscHZDZlltYTNHRFZTRlBBMkg4STFCaGhZeXNiWWxPdnNyRmZoWGtrMFVEeHhyN2VaMGdDcTBVd0Q4NEJyb1Z6YTJCWWlfY1Q5cWphVEdwUUNmZnlFd1U3ZmI5Ym9TQlFWaA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma closes $172.5 million IPO on NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxON3JpdlVXeXVaQXpsNi10Q3dXRXczd2RGRjJTZGZkZEd0OXhkX0tncHlxZFV3b1VwcFdwVnFKRzJqSEliRFpQLU12NkhYNHdKdmJCNzJTdHY5M1drTTkyb1dPOVlzOFpSb3EtQy1kaVM5TGxnV0dObDlPSnBJWVZhLUZzSWdHTXFTYVdzQ2ZGS05kTDZBbTZjTXhLZjJfcmtxWGw4U2pCcEdwcHNYYmlaenV3?oc=5", "source_name": "Investing.com", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc (SGP) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE81YzBfTF9QekdOUldkb3FqVHZNX0I0UE50cFgwbEVWN3hNWHhxaVEwa2RELXhzRWJ2T2N3M2diamlmSzQ1SnR6VFBoRlhRN1dvYkxaeU1R?oc=5", "source_name": "Gotrade", "published_at": "2026-02-07T21:08:16+00:00", "published_display": "07 Feb 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma - SGP - Stock Price & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE0wRThsc3dBaDlvZjNaS3NSQlRzTm12OW1KeldRRHF3aGJRZFJ4cU9MaUQtZWFid0ZyT2gtTUNwV1FWMW5xOGFlTEE1MEJ0TDA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-02-06T17:51:02+00:00", "published_display": "06 Feb 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma shares surge 50% in Nasdaq debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOMUJncXZELTBKMmJIVy1HWlduU1dkeHNuUEl3RWwtb3h4X0ZTSTE2Y0RCOTJMUzBONXZMTG5kMXRyVDJnRnMwQXRnUW9KVVMzMlFxcER1aTZOb1dqUV9CVGVmSDRMYkFYYXotanV3aW1BNE42TmxBUTdQdTlGdmtCWENmQzJZVVVvNXBlcU1IdjJmbVZBZ2ZORGhBX1lEdlFEcFJuWmFuenh5SC1WU2c?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOVXR4ZzA4X00yTGlFMmVGcXRDRExVVDk0UVdVNDVrVXlyRWo2SDRDcHdGYzh6OVFZbnRiQ3Y2TVp6X0MyX2lUSFdMSDFUYXcxWlRyVXJxTm1wS3BDWktaSHA4V1hGSEhQUkgtbU0xdllPUkRRYjdJMDBGMjZQa1g4d1k1OHBrQ3R1YTdiUzRFRWw1MHZuUS1QZVpjTWI5RGNiX3h6N0daWGRsY2wxZGR6Vg?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Rings the Nasdaq Stock Market Opening Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQaHRzQzBBTnBuck1lSFRvRVNrUzdNRUhFSzlGZ1J5Q0RxdXBsSzZSM2tBUGdKNzB6ZTZUelFBdkpFdTNUMV9FbUZkQnk2NUVXT0NJSHZ6WWsxdlB1MjVRLUs5UnZtY1Bwcll0Yms3czFpQmVKX1h6TUp0VFpEXzBHdVRfNDM2b0tYTXFiMg?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPQmFIRVZ4VFhhQUNLU2pocGVCWUZPNkVIdjdtanZNMVlCUmNwWXdwejRSbWJkQmtuY2JoaEFXekQ3eW82WTFiOWhJQTBoVlBXZGNCMkJ1RExFUGFOX1pLT0ZVZEY5MWNFMVNUQUhHc1NvczByTWYxUVBERV81Q1NmcVFSSGp4b1NndjQ4eXlR?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Announces Pricing of Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPYTRjX1N3QTU0dkJpTWVMNWMtN0Q3N0VGVkxURUdHc1VYQmRIYUtEUlI4cUZ5cmFOUTRsa1duUjZtamVQNzVPcjlrQTAwRFVrdW1seFZMcDZQcG44RHJVVFktNEp3T1Y2NWx1QkNPQ3c2V2JIdWdaUS1XT3lHMFNSNmRzYUlvcTBMdVZhUHNoZzQ2NTJPWEdtUUJuYW1SUmpENjVhYmEzeGE2R3hRT2FJblo1bHktSkhMRHpGNjZnZFJfZlltVjdGbm1wWUo?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates (Pending: SGP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUjNOTXhtenZsUTVlY2xMdzUyOFZOTkVOcU9SeGhTb0VpSXI1dGpUVkN2V0c4UlVENkp2NmtaT29idk9GU2MzRWpyTlpNZWEzZFJsU0NRRFl6bHVwRTlGckY5U2Z6ODhtVW16NHBRc25qY2l2eGp6Wno0b2tTaU45Z2psaVY2Sjk3dTR4MmVFTEdpQXRCR0xZV24wUHc4S0daaHZsMkM4Zm1WVWMtUlBHS2NR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Top Spyglass Pharma (SGP) Competitors 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE44LThrdVVQVlpTN0Y4SEtoZEc2WDF2QS16Um5hUDRFSHVXVGg2THJsTUtyQVh5QVdWR084WE9iNm0zTHJIS3BXOVVfRi0yeENkaC0wNUFDUVlwNHltQXMtZExHcWNmMmppZDVFb09STmRvTjRvSFdsS0hDOVNKS00?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-14T01:19:40+00:00", "published_display": "14 Jul 2026 01:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index", "summary": "SpyGlass Pharma, Inc. (NasdaqGS:SGP) has been added to the Russell Microcap Growth Benchmark Index. This inclusion follows several other additions for the company to various Russell indices, including the Russell 2000, Russell Microcap Value, and Russell 3000E. SpyGlass Pharma is", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08cf327", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T18:39:59", "published_display": "29 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index", "summary": "SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been added to the Russell 2000 Index. This inclusion follows several other recent index additions, including the S&P Global BMI Index and the S&P TMI Index, highlighting the company's growing recognition in the financial markets. The opht", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-2000-index-ce7f5fdfdc8ef426", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T17:57:00", "published_display": "29 Jun 2026 17:57", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark", "summary": "SpyGlass Pharma, Inc. (NasdaqGS:SGP) has been added to the Russell 2000 Value Benchmark, according to an announcement published on MarketScreener. The company specializes in ophthalmic drug delivery, with its flagship product being the SpyGlass Drug Delivery Platform designed to ", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-2000-value-benchmark-ce7f5fdfdb89f020", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:12:03", "published_display": "29 Jun 2026 16:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark", "summary": "SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been included in the Russell 2000 Growth Benchmark. This news follows several other recent updates for the company, including presentations at major healthcare conferences and its addition to the S&P Global BMI Index and S&P TMI Index, hi", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-russell-2000-growth-benchmark-ce7f5fded18cf225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:03", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article provides limited financial information for SpyGlass Pharma, Inc. (NASDAQ: SGP), specifically mentioning its \"Price to earnings forward.\" The full data for this metric is not displayed in the provided text. The page appears to be a financial data portal from TradingVi", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T07:41:32", "published_display": "29 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP)", "summary": "This article provides key financial data and analyst estimates for SpyGlass Pharma, Inc. (NASDAQ: SGP). It covers the company's current stock price, historical performance, future price forecasts from analysts, and recent financial results including earnings and revenue. The info", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:56", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article focuses on the \"Price to sales forward\" financial metric for SpyGlass Pharma, Inc. (NASDAQ: SGP). It appears to be a stub or a section of a larger financial data page, indicating that this specific data point is provided by TradingView, with underlying data from ICE ", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:40:56", "published_display": "26 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article provides financial data for SpyGlass Pharma, Inc. (NASDAQ: SGP), specifically focusing on its enterprise value to revenue forward. The content is presented within the context of a financial platform, indicating a focus on market analytics and company performance metr", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T18:39:59", "published_display": "26 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of SpyGlass Pharma, Inc. \u2013 NASDAQ:SGP", "summary": "This article provides the \"Price to book forward\" for SpyGlass Pharma, Inc. (NASDAQ: SGP). It appears to be a financial data snippet from TradingView, indicating no trades and a market closed status, presenting the fundamental value for the specified period.", "url": "https://www.tradingview.com/symbols/NASDAQ-SGP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:26", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP", "summary": "As of June 15, 2026, Spyglass Pharma (SGP) had a short interest of 1.01 million shares, representing 3.03% of its public float, an 11.57% decrease from the previous report. The short interest ratio is 14.3 days to cover. This indicates that while still considered high, investor s", "url": "https://www.marketbeat.com/stocks/NASDAQ/SGP/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-26T03:40:22", "published_display": "26 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index", "summary": "SpyGlass Pharma, Inc. (NasdaqGS: SGP) has been included in the S&P Global BMI Index. The company, which specializes in ophthalmic drug delivery solutions, was added to the index as announced on June 21, 2026, at 10:30 PM EDT. This inclusion highlights SpyGlass Pharma's growing pr", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-nasdaqgs-sgp-added-to-s-p-global-bmi-index-ce7f5cd3d881f626", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T02:41:28", "published_display": "22 Jun 2026 02:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Shannon Trevi\u00f1o as general counsel to support Phase 3 trials and commercialization plans.", "summary": "SpyGlass Pharma has appointed Shannon Trevi\u00f1o as its new general counsel, leveraging her extensive legal and leadership experience, including guiding Inari Medical through a $4.9 billion acquisition. Her appointment is strategic as SpyGlass advances its BIM-IOL System through Pha", "url": "https://pluang.com/en/news-feed/spyglass-pharma-tunjuk-shannon-trevino-sebagai-general-counsel", "source_name": "Pluang", "published_at": "2026-06-16T11:40:48", "published_display": "16 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GC who helped guide Inari through $4.9B Stryker acquisition joins SpyGlass", "summary": "SpyGlass Pharma (Nasdaq: SGP) has appointed Shannon Trevi\u00f1o as its new General Counsel. Trevi\u00f1o previously served as General Counsel at Inari Medical, where she played a key role in its $4.9 billion acquisition by Stryker, and brings extensive experience in corporate, M&A, and se", "url": "https://www.stocktitan.net/news/SGP/spy-glass-pharma-appoints-shannon-trevino-as-general-m51ywidinhkb.html", "source_name": "Stock Titan", "published_at": "2026-06-16T00:09:11", "published_display": "16 Jun 2026 00:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Taps Shannon Trevi\u00f1o as General Counsel", "summary": "SpyGlass Pharma Inc., an Aliso Viejo-based biopharmaceutical company, has appointed Shannon Trevi\u00f1o as its new General Counsel. Trevi\u00f1o previously served as general counsel and corporate secretary at Inari Medical, which was acquired by Stryker Corp. for $4.9 billion. This appoin", "url": "https://www.ocbj.com/healthcare/spyglass-taps-shannon-trevino-as-general-counsel/", "source_name": "Orange County Business Journal", "published_at": "2026-06-15T17:09:45", "published_display": "15 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Shannon Trevi\u00f1o as general counsel", "summary": "SpyGlass Pharma has appointed Shannon Trevi\u00f1o as its new general counsel. Trevi\u00f1o brings extensive experience from Inari Medical, where she oversaw legal and compliance, including a $4.9 billion acquisition by Stryker, and her prior work advising early and growth-stage companies.", "url": "https://www.investing.com/news/company-news/spyglass-pharma-appoints-shannon-trevino-as-general-counsel-93CH-4742019", "source_name": "Investing.com", "published_at": "2026-06-15T13:10:30", "published_display": "15 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc. Announces Appointment of Shannon Trevi\u00f1o to General Counsel", "summary": "SpyGlass Pharma, Inc. has announced the appointment of Shannon Trevi\u00f1o as its new General Counsel. Ms. Trevi\u00f1o brings extensive experience in corporate, M&A, and securities law within the healthcare sector, having previously served as General Counsel and Corporate Secretary at In", "url": "https://www.marketscreener.com/news/spyglass-pharma-inc-announces-appointment-of-shannon-trevi-o-to-general-counsel-ce7f5cdedd8ff72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-15T13:09:45", "published_display": "15 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Shannon Trevi\u00f1o as general counsel By Investing.com", "summary": "SpyGlass Pharma has appointed Shannon Trevi\u00f1o as its new general counsel. Trevi\u00f1o brings extensive experience, having previously served as General Counsel and Corporate Secretary at Inari Medical, where she managed legal and compliance during a major acquisition. SpyGlass Pharma,", "url": "https://ca.investing.com/news/stock-market-news/spyglass-pharma-appoints-shannon-trevino-as-general-counsel-93CH-4690697", "source_name": "Investing.com Canada", "published_at": "2026-06-15T12:09:45", "published_display": "15 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing", "summary": "SpyGlass Pharma has appointed Mike Pinder as Vice President, Marketing, effective May 18, 2026. Pinder brings over 20 years of ophthalmology commercial launch experience and will be responsible for building and leading the company's marketing function as it advances its Bimatopro", "url": "https://www.visionmonday.com/eyecare/article/spyglass-pharma-appoints-mike-pinder-as-vice-president-marketing/", "source_name": "VisionMonday.com", "published_at": "2026-06-03T04:09:39", "published_display": "03 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com", "summary": "SpyGlass Pharma announced the appointment of Mike Pinder as VP of marketing. Pinder brings significant ophthalmology commercial launch experience and will lead the marketing function as the company advances its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials. This", "url": "https://za.investing.com/news/stock-market-news/spyglass-pharma-appoints-mike-pinder-as-vp-of-marketing-93CH-4310174", "source_name": "Investing.com South Africa", "published_at": "2026-06-02T18:39:16", "published_display": "02 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma appoints Mike Pinder as VP of marketing", "summary": "SpyGlass Pharma has appointed Mike Pinder as Vice President of Marketing. Pinder brings over 20 years of ophthalmology commercial launch experience and will lead the marketing function as the company advances its Bimatoprost Drug Pad-IOL System through Phase 3 clinical trials. Th", "url": "https://www.investing.com/news/company-news/spyglass-pharma-appoints-mike-pinder-as-vp-of-marketing-93CH-4721851", "source_name": "Investing.com", "published_at": "2026-06-02T12:39:20", "published_display": "02 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Drop-free glaucoma BIM-IOL system taps veteran marketer", "summary": "SpyGlass Pharma (Nasdaq: SGP) has appointed Mike Pinder as Vice President, Marketing, to lead commercialization efforts for its Bimatoprost Drug Pad-IOL System (BIM-IOL System). Pinder brings over 20 years of ophthalmology marketing experience from companies like Astellas, Novart", "url": "https://www.stocktitan.net/news/SGP/spy-glass-pharma-appoints-mike-pinder-as-vice-president-vnpc0wi41cbx.html", "source_name": "Stock Titan", "published_at": "2026-06-02T11:39:20", "published_display": "02 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma (SGP) Slides 2.29% as Stock Approaches Critical Support at $17.0 - Liquidity Sweep", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPQnNLTjZiREJ5LXVYc2tMYzVvR0I3QVhZQlNsVTc5TkNFdE45SnZTdWEyNkllRmkteG5OTjFvMlVzN0hNRlg5V1FlTWdlbU4ycVRxT3dLQW52cTF0eDUxVlpoRngwX0NZXzY0WWhZVHl5ZTZIc0taOU8wVnA4UHRfYjZ5dkRDcnFJWElqM1kxWm5DWGI0d1RSUHV6ZUp0Z0RBeVJteXVUSTY0dlFLcG5oYldR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma to Participate in Upcoming Investor Conferences", "summary": "SpyGlass Pharma, Inc. (Nasdaq: SGP) announced its participation in three upcoming investor conferences in May and June 2026: the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. Ex", "url": "https://www.sahmcapital.com/news/content/spyglass-pharma-to-participate-in-upcoming-investor-conferences-2026-05-21", "source_name": "Sahm", "published_at": "2026-05-26T17:39:20", "published_display": "26 May 2026 17:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma execs set for three June healthcare investor events", "summary": "SpyGlass Pharma (Nasdaq: SGP) announced its executive management will participate in three upcoming investor conferences focused on healthcare and ophthalmology in May and June 2026. These events include the Stifel 2026 Virtual Ophthalmology Forum, the Jefferies Global Healthcare", "url": "https://www.stocktitan.net/news/SGP/spy-glass-pharma-to-participate-in-upcoming-investor-v6a13ma3qq99.html", "source_name": "Stock Titan", "published_at": "2026-05-21T11:59:58", "published_display": "21 May 2026 11:59", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Secures Billing Code for IOL Platform", "summary": "SpyGlass Pharma Inc. has secured a new add-on Category III CPT Code for its intraocular lens (IOL) platform, which delivers glaucoma medication for up to three years. The Aliso Viejo-based company is currently in Phase 3 trials and aims for FDA submission by 2028 and commercial l", "url": "https://www.ocbj.com/healthcare/spyglass-secures-billing-code-for-iol-platform/", "source_name": "Orange County Business Journal", "published_at": "2026-05-19T23:38:56", "published_display": "19 May 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma: New add-on CPT code supports BIM-IOL System", "summary": "The American Medical Association has approved a new add-on Category III CPT code for intraocular lens prosthesis-mounted drug-eluting implants, supporting SpyGlass Pharma's investigational Bimatoprost Drug Pad-IOL (BIM-IOL) System. This system aims to deliver bimatoprost for thre", "url": "https://glance.eyesoneyecare.com/stories/2026-05-19/spyglass-pharma-new-add-on-cpt-code-supports-bim-iol-system/", "source_name": "Eyes On Eyecare", "published_at": "2026-05-19T18:38:56", "published_display": "19 May 2026 18:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System", "summary": "SpyGlass Pharma announced that the AMA's CPT Editorial Panel approved a new add-on Category III CPT code for its Bimatoprost Drug Pad-IOL System (BIM-IOL System). This code will support reimbursement for surgeons using the device in conjunction with cataract surgery, aiming to im", "url": "https://finance.yahoo.com/sectors/healthcare/articles/spyglass-pharma-announces-add-category-120000782.html", "source_name": "Market source", "published_at": "2026-05-18T20:10:26", "published_display": "18 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/spyglass-pharma-reports-first-quarter-200500962.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE85QlJzV0Iwb1pibVMzWGNtQnFkczFCZXd3aC15dTRaOHBxUHFKSS1vSUpaNUZieUVsLVJvTmpnMWdobFg4cVJtVWMzRi1CMFc2YlRWcFdDbVNnWDR6VEZRZFZQODE?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-18T04:54:39+00:00", "published_display": "18 Feb 2026 04:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE5QMDVYbjlnZUxpc1BHMzlQampPbU13dFRqcUg2Vi11S1dXbHV0ODVUeGdvbjFLVDhxWHBRLWVVV0lpVDJPYlJvbldlQlhOYXc4UjhUY19lYlU?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-17T17:53:41+00:00", "published_display": "17 Feb 2026 17:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma (SGP) Stock Forecast and Price Target 2026 $SGP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTFA3M3RUa1Y5NUtfNWI5czZRcDdSMFc4bGRDcGJnZVdhQTR2eU43Slo3VTRNM3BUaHBZUGtlOTFsS0ZyWU5HejFiUjJCNHVJR1VxT0VINnJ6QkhiZXR3dFNOZUJhN3o?oc=5", "source_name": "MarketBeat", "published_at": "2026-02-17T17:48:38+00:00", "published_display": "17 Feb 2026 17:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Announces Closing of Initial Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAJBVV95cUxOTU1pV0YwTzBOM0FSQUFvMUlqS25TMDBRMksyRGVYS00wYzJaTkdMdlY0WXE2QXhVU2I1czJIWEIwOHhmNTAzdWRnSktha3IxNTJWV19nVEpJdm1zZHdPTmxkNFpoYWl5cG1MUXlEeUMyVkNfeUw2V2h2UnRfSERhMXc3LXQwb0EzZzJLQldJVXZKenhzYnhMaU1BaDZpVFA3c2d0bWk3MUpVRUM4S1lZbk1XOGRJYXdpa210LTBVMTFodHdRVC11T2xqbWVpYTVMdWZscHZDZlltYTNHRFZTRlBBMkg4STFCaGhZeXNiWWxPdnNyRmZoWGtrMFVEeHhyN2VaMGdDcTBVd0Q4NEJyb1Z6YTJCWWlfY1Q5cWphVEdwUUNmZnlFd1U3ZmI5Ym9TQlFWaA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma closes $172.5 million IPO on NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxON3JpdlVXeXVaQXpsNi10Q3dXRXczd2RGRjJTZGZkZEd0OXhkX0tncHlxZFV3b1VwcFdwVnFKRzJqSEliRFpQLU12NkhYNHdKdmJCNzJTdHY5M1drTTkyb1dPOVlzOFpSb3EtQy1kaVM5TGxnV0dObDlPSnBJWVZhLUZzSWdHTXFTYVdzQ2ZGS05kTDZBbTZjTXhLZjJfcmtxWGw4U2pCcEdwcHNYYmlaenV3?oc=5", "source_name": "Investing.com", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma, Inc (SGP) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE81YzBfTF9QekdOUldkb3FqVHZNX0I0UE50cFgwbEVWN3hNWHhxaVEwa2RELXhzRWJ2T2N3M2diamlmSzQ1SnR6VFBoRlhRN1dvYkxaeU1R?oc=5", "source_name": "Gotrade", "published_at": "2026-02-07T21:08:16+00:00", "published_display": "07 Feb 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma - SGP - Stock Price & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE0wRThsc3dBaDlvZjNaS3NSQlRzTm12OW1KeldRRHF3aGJRZFJ4cU9MaUQtZWFid0ZyT2gtTUNwV1FWMW5xOGFlTEE1MEJ0TDA?oc=5", "source_name": "The Motley Fool", "published_at": "2026-02-06T17:51:02+00:00", "published_display": "06 Feb 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spyglass Pharma shares surge 50% in Nasdaq debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOMUJncXZELTBKMmJIVy1HWlduU1dkeHNuUEl3RWwtb3h4X0ZTSTE2Y0RCOTJMUzBONXZMTG5kMXRyVDJnRnMwQXRnUW9KVVMzMlFxcER1aTZOb1dqUV9CVGVmSDRMYkFYYXotanV3aW1BNE42TmxBUTdQdTlGdmtCWENmQzJZVVVvNXBlcU1IdjJmbVZBZ2ZORGhBX1lEdlFEcFJuWmFuenh5SC1WU2c?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eye Care Firm SpyGlass Pharma Soars 50% After $150 Million IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOVXR4ZzA4X00yTGlFMmVGcXRDRExVVDk0UVdVNDVrVXlyRWo2SDRDcHdGYzh6OVFZbnRiQ3Y2TVp6X0MyX2lUSFdMSDFUYXcxWlRyVXJxTm1wS3BDWktaSHA4V1hGSEhQUkgtbU0xdllPUkRRYjdJMDBGMjZQa1g4d1k1OHBrQ3R1YTdiUzRFRWw1MHZuUS1QZVpjTWI5RGNiX3h6N0daWGRsY2wxZGR6Vg?oc=5", "source_name": "Bloomberg.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Rings the Nasdaq Stock Market Opening Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQaHRzQzBBTnBuck1lSFRvRVNrUzdNRUhFSzlGZ1J5Q0RxdXBsSzZSM2tBUGdKNzB6ZTZUelFBdkpFdTNUMV9FbUZkQnk2NUVXT0NJSHZ6WWsxdlB1MjVRLUs5UnZtY1Bwcll0Yms3czFpQmVKX1h6TUp0VFpEXzBHdVRfNDM2b0tYTXFiMg?oc=5", "source_name": "Nasdaq", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPQmFIRVZ4VFhhQUNLU2pocGVCWUZPNkVIdjdtanZNMVlCUmNwWXdwejRSbWJkQmtuY2JoaEFXekQ3eW82WTFiOWhJQTBoVlBXZGNCMkJ1RExFUGFOX1pLT0ZVZEY5MWNFMVNUQUhHc1NvczByTWYxUVBERV81Q1NmcVFSSGp4b1NndjQ4eXlR?oc=5", "source_name": "Fierce Biotech", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Announces Pricing of Initial Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPYTRjX1N3QTU0dkJpTWVMNWMtN0Q3N0VGVkxURUdHc1VYQmRIYUtEUlI4cUZ5cmFOUTRsa1duUjZtamVQNzVPcjlrQTAwRFVrdW1seFZMcDZQcG44RHJVVFktNEp3T1Y2NWx1QkNPQ3c2V2JIdWdaUS1XT3lHMFNSNmRzYUlvcTBMdVZhUHNoZzQ2NTJPWEdtUUJuYW1SUmpENjVhYmEzeGE2R3hRT2FJblo1bHktSkhMRHpGNjZnZFJfZlltVjdGbm1wWUo?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SpyGlass Pharma Sees IPO Ahead For Its Ocular Pressure Treatment Candidates (Pending: SGP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQUjNOTXhtenZsUTVlY2xMdzUyOFZOTkVOcU9SeGhTb0VpSXI1dGpUVkN2V0c4UlVENkp2NmtaT29idk9GU2MzRWpyTlpNZWEzZFJsU0NRRFl6bHVwRTlGckY5U2Z6ODhtVW16NHBRc25qY2l2eGp6Wno0b2tTaU45Z2psaVY2Sjk3dTR4MmVFTEdpQXRCR0xZV24wUHc4S0daaHZsMkM4Zm1WVWMtUlBHS2NR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 51, "sentiment_summary": {"positive": 19, "negative": 1, "neutral": 31, "score": 59, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 22.52, "latest_week": "2026-07-10", "one_week_move": 17.6, "four_week_move": 22.1, "twelve_week_move": -9.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.0, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": -3.2, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 28.2143, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+17.6% over one week, +22.1% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "www.marketscreener.com", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "MarketBeat", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Orange County Business Journal", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 42}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "42", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+17.6% over one week, +22.1% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Top Spyglass Pharma (SGP) Competitors 2026"}], "updated_at": "2026-07-17T05:46:15.255469+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}